- The Co-Production and Evaluation of the Computerised Cognitive Assessment for Preclinical Alzheimer’s Disease (CoCoA-PAD) — Recruiting • Neurology • NCT07598617.
- What is being tested: Development and evaluation of CoCoA-PAD, a computerised cognitive assessment tool designed to identify individuals in the preclinical stages of Alzheimer's disease before symptoms become clinically apparent.
- Patient eligibility overview: The trial involves co-production with healthcare professionals and patients to ensure the assessment is practical and acceptable for NHS implementation, with focus on identifying asymptomatic individuals at risk of early-stage Alzheimer's disease.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Background. Healthcare professionals can now diagnose the earliest stages of Alzheimer's disease (early-AD) and new drugs are effective at slowing the disease. The National Health Service (NHS) in the United Kingdom has started to develop plans for how to implement these key achievements into clinical practice, so that patients can receive timely diagnosis and treatment. Cognitive assessments measure someone's memory and thinking skills and are required for an early-AD diagnosis. There are concerns that the NHS does not have the workforce to deliver cognitive assessments, and that this will delay…
- Recruitment Criteria for Subjective Cognitive Decline and Mild Cognitive Impairment Subjective Cognitive Decline Inclusion Criteria * >3.38 on IQCODE Self-Report items 1-7 (PROTECT) OR * ≥4 on SCD-Q9 (non-Protect) AND * Age ≥65 years * Onset of SCD within the last 5 years * English as a first language * Normal demographically adjusted performance on standardised cognitive tests * Specific Race and Education (using stratified sampling approach)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.